ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 1 filers reported holding ACCELERON PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $213,000 | -91.8% | 1,236 | -94.0% | 0.00% | -93.9% |
| Q2 2021 | $2,598,000 | +382.0% | 20,703 | +51.7% | 0.05% | +172.2% |
| Q3 2019 | $539,000 | +53.1% | 13,649 | +64.5% | 0.02% | +100.0% |
| Q4 2017 | $352,000 | -88.1% | 8,297 | -89.6% | 0.01% | -88.2% |
| Q3 2017 | $2,966,000 | +662.5% | 79,462 | +520.8% | 0.08% | +533.3% |
| Q2 2017 | $389,000 | +61.4% | 12,800 | +40.6% | 0.01% | +71.4% |
| Q1 2017 | $241,000 | +12.6% | 9,105 | +8.5% | 0.01% | +16.7% |
| Q4 2016 | $214,000 | -12.7% | 8,389 | +24.1% | 0.01% | 0.0% |
| Q3 2016 | $245,000 | -49.0% | 6,758 | -52.2% | 0.01% | -40.0% |
| Q2 2016 | $480,000 | +63.8% | 14,140 | +27.4% | 0.01% | +42.9% |
| Q1 2016 | $293,000 | +35.6% | 11,096 | +150.1% | 0.01% | +16.7% |
| Q4 2015 | $216,000 | +2.4% | 4,436 | -47.6% | 0.01% | -14.3% |
| Q3 2015 | $211,000 | – | 8,469 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |